Head-to-head · free

First Tracks Biotherapeutics Inc vs Vera Therapeutics, Inc.

TRAX vs VERA — return on capital, cash generation, margins and balance sheet side by side.

TRAX

2 / 2

measures where TRAX leads

VERA

0 / 2

measures where VERA leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTRAXVERA · FY2025
Revenue——
Net income—(299.6M)
Revenue growth (yearly, multi-year)——
Free cash flow—(241.7M)
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity-40.9%-50.7%
Gross margin——
Operating margin——
Net debt / EBITDA0.69x0.89x

Figures are as reported by each company; latest fiscal year shown.

Where First Tracks Biotherapeutics Inc's cash went

Not reported yet.

Full TRAX profile →

Where Vera Therapeutics, Inc.'s cash went (FY2025)

Capital spending
$630000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full VERA profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons